Kiora Pharmaceuticals, Inc. (KPRX) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
KPRX Revenue Growth
KPRX Revenue Analysis (2013–2024)
As of May 8, 2026, Kiora Pharmaceuticals, Inc. (KPRX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, KPRX's 5-year compound annual growth rate (CAGR) stands at +42.9%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $16.0 million in 2024, representing a new all-time high.
When compared to Healthcare sector peers including OCUL (-12.8% YoY), and LENZ. Compare KPRX vs OCUL →
KPRX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| KPRXCurrent | $0 | - | +42.9% | 28.2% | |
 OCUL | $52M | -12.8% | +24.4% | -521.0% | |
 LENZ | $19M | - | - | -477.5% |
KPRX Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $16.0M | - | $16.0M | 100.0% | $4.5M | 28.2% |
| 2023 | $0 | - | $0 | - | $-12,586,896 | - |
| 2022 | $0 | - | $0 | - | $-12,309,523 | - |
| 2021 | $0 | -100.0% | $0 | - | $-14,235,768 | - |
| 2020 | $12K | -99.6% | $-3,260,592 | -27038.7% | $-6,868,868 | -56960.5% |
| 2019 | $2.7M | +62.5% | $2.7M | 99.8% | $-7,000,975 | -260.6% |
| 2018 | $1.7M | +305.5% | $-6,403,243 | -387.5% | $-10,844,701 | -656.3% |
| 2017 | $408K | -39.1% | $-9,922,831 | -2434.9% | $-14,559,239 | -3572.7% |
| 2016 | $669K | - | $-7,753,283 | -1158.5% | $-13,346,846 | -1994.3% |
| 2015 | $0 | - | $-1,257 | - | $-6,677,608 | - |
See KPRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KPRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KPRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonKPRX — Frequently Asked Questions
Quick answers to the most common questions about buying KPRX stock.
Is KPRX's revenue growth accelerating or slowing?
KPRX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: +42.9%.
What is KPRX's long-term revenue growth rate?
Kiora Pharmaceuticals, Inc.'s 5-year revenue CAGR of +42.9% reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is KPRX's revenue distributed by segment?
KPRX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.